The Protocol Specific Research Support (PSRS) funding of the CCSG supports research personnel dedicated to the development, implementation, conduct, and completion of high priority, innovative investigator-initiated phase I clinical trials. This resource is of high priority to the Cancer Center given the renewed and strong commitment to translational research and early phase clinical studies. In particular, this funding mechanism is critical for the YCC to fulfill its mission of translating the most exciting discoveries and science coming from YCC research labs into the clinical setting. As such, these types of translational clinical studies are complex in nature and design, as they incorporate important correlative, biologic, pharmacokinetic, and pharmacodynamic studies. While the YCC PSRS has always supported investigatorinitiated studies, the PSRS anticipates a significant increase in investigator-initiated clinical trials during the next funding period with an increased need to support these investigators. The main goals of the PSRS are to (1) provide nursing and data management support for investigator-initiated pilot phase I clinical studies, (2) provide assistance to investigators in the development and start-up of innovative studies, (3) provide assistance in eligibility determination and recruitment of patients for these clinical studies, (4) ensure the safe conduct of clinical research by monitoring patients, (5) provide source documentation for timely and complete entry in the PRS, (6) report study results, and (7) ensure compliance with federal and regulatory mandates. This effort .will require research nurses and data managers who have experience to ensure the safety, integrity, and success of these important studies. The continuity of staffing is essential to the success of studies presently on-going and to those that will be developed in the next funding period. The PSR interacts closely with the other key elements of the YCC clinical trials program, which include the Clinical Research Services (CRS) and the Protocol Review and Monitoring System (PRMS), and working together in an integrated, highly coordinated manner, these 3 elements serve as the cornerstone for the YCC clinical investigations program, The PSRS also interacts closely with the YCC Clinical/Translational Research Programs, including Developmental Therapeutics (DT), Radiobiology &Radiotherapy (R&R), and Immunology &Immunotherapy (l&l). The SPORE in Skin Cancer with a special focus on melanoma showcases the highly interdisciplinary, interprogrammatic collaborations between the DT, l&l, and Cancer Prevention and Control Programs and highlights the focus on developing innovative clinical studies that stem directly from YCC pre-clinical laboratory investigation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-31
Application #
7916708
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
31
Fiscal Year
2009
Total Cost
$101,750
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331

Showing the most recent 10 out of 675 publications